Dietary and Therapeutic Management of Glycogen Storage Disease Type IX: Analysis of a Systematic Review
Open Access
Abstract
Background/Objectives: Glycogen storage disease type IX (GSD IX) is an inherited metabolic disorder characterized by marked clinical heterogeneity and variable severity. Dietary therapy is considered the cornerstone of management, but evidence on treatment strategies, efficacy, and safety remains limited. This study aimed to systematically synthesize available data on therapeutic approaches and clinical outcomes in GSD IX. Methods: A focused analysis of treatment-related data was conducted from a previously performed PRISMA-based systematic review. Clinical studies reporting treatment and follow-up data in genetically confirmed GSD IX patients were included. Results: Among 400 patients identified in the original review, 129 from 26 studies had treatment and follow-up data available. Dietary management combined with uncooked cornstarch (UCCS) was the most common approach (96.1%), with highly heterogeneous protocols. Hepatic manifestations improved in 59/129 (45.7%) of patients, and hypoglycemia in 45/129 (34.9%). Growth outcomes were variable, with catch-up growth in 14.0% and persistent impairment in 19.4%, although data were often missing. Muscle involvement was rarely assessed. No treatment-related adverse events were reported. However, disease-related complications were described, including liver cirrhosis, neurological involvement, osteopenia/osteoporosis, and two deaths in GSD IXa patients. Conclusions: Dietary therapy combined with UCCS remains the mainstay of treatment in GSD IX and is associated with improvement in key clinical domains. However, evidence is limited, heterogeneous, and largely based on small studies. Data on modified cornstarch formulations, such as Glycosade®, are scarce. Prospective studies and standardized treatment protocols are needed to support evidence-based management.Keywords
This publication has 43 references indexed in Scilit:
- Glucose dynamics in glycogen storage disease type IXa with novel PHKA2 variants: insights from our experience and a comprehensive review of the disease spectrumHormones, 2025
- A novel PHKA1 mutation associating myopathy and cognitive impairment: Expanding the spectrum of phosphorylase kinase b (PhK) deficiencyJournal of the Neurological Sciences, 2021
- Autism: Screening of inborn errors of metabolism and unexpected resultsAutism Research, 2021
- Liver histology in children with glycogen storage disorders type VI and IXDigestive and Liver Disease, 2021
- Clinical and genetic characteristics of 17 Chinese patients with glycogen storage disease type IXaGene, 2017
- Clinical and Molecular Variability in Patients with PHKA2 Variants and Liver Phosphorylase b Kinase Deficiency2017
- Glycogen storage disease type IX: High variability in clinical phenotypeMolecular Genetics and Metabolism, 2007
- Variability of biochemical and clinical phenotype in X-linked liver glycogenosis with mutations in the phosphorylase kinase PHKA2 geneHuman Genetics, 1998
- The long‐term outcome of patients with glycogen storage diseasesJournal of Inherited Metabolic Disease, 1990
- Growth and endocrine changes in the hepatic glycogenosesEuropean Journal of Pediatrics, 1982